Trial Profile

Interventional, Open-label, Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LU AF-35700 (Primary)
Indications Schizophrenia
Focus Adverse reactions
Acronyms Debut
Sponsors Lundbeck A/S

Most Recent Events

01 Oct 2022 Results (n=1628) assessing efficacy and safety (NCT02717195 followed by a one year open-label safety extension NCT0289242) of Lu AF35700 in patients with treatment-resistant schizophrenia, published in the Schizophrenia Research.
09 Dec 2019 Status changed from active, no longer recruiting to completed.
10 Nov 2019 This trial was completed in Spain and Czech Republic, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com